Oral infections, dental caries, periodontitis, and opportunistic oral candidiasis comprise a significant public health problem of a global scale that is further aggravated due to antimicrobial resistance and the side effects associated with conventional synthetic drugs. Clove oil, isolated from the dried flowers of Syzygium aromaticum, is proposed as a multi-targeted phytotherapeutic approach for preventive and remedial dental care. Its phytochemical features, powered by phenylpropenes like eugenol (50-90%) accompanied by small molecules like eugenyl acetate and β-caryophyllene, exhibit combined mechanisms of action: rapid local analgesia through voltage-gated Na+ channel blockers and TRPV1 receptor inactivation, modulation of inflammatory cascades through inhibition of NFκB transcription and COX-2 activity, neutralizassstion of free radicals and also diminish the acid-induced decalcification of dental enamel. Its antimicrobial properties against primary oral pathogens like Streptococcus mutans, Porphyromonas gingivalis and Candida albicans work by permeabilizing cytoplasmic membranes of bacteria and C. albicans, inactivating streptococcal glucosyltransferases, degrading exopolysaccharidic matrices and blocking quorum sensing signalling molecules, although they have limitations related to volatile degradation, aqueous insolubility, unpleasant organoleptic characteristics and high-dose-mediated oral mucosal cytotoxicity. Advanced nanoemulsion-based systems and mucoadhesive nanoemulgels provide a potential remedy to address such factors, enhance dispersibility in saliva, promote delivery into biofilms and provide sustained release on the target oral niches. Standardization of bioavailable component concentrations and proper clinical investigation of these nano-delivery formulations are essential steps to their mainstream implementation in oral healthcare.